Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|October 18, 2018
3 New Studies About Depression and Lifestyle
Author(s)Mark L. Fuerst
Three new studies highlight the link between depression and opioid overdoses; “early birds” are less prone to depression; and consuming fish may reduce the risk of depression.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
3
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5